Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
- Response deadline
- Sep 28, 2026 Due in 27 days
- Date posted
- Jun 30, 2026
- Source
- Open notice
Description
This is a non-competitive funding opportunity intended to fund a single award. The National Institute of Neurological Disorders and Stroke is announcing its intent to issue a single source cooperative agreement award to Massachusetts General Hospital to support the renewal of the Post-Stroke Vascular Cognitive Impairment & Dementia (VCID) program, an ongoing, multi-site clinical research initiative designed to elucidate mechanisms linking stroke to subsequent cognitive impairment and dementia. The award will enable completion of the scientific aims initiated under the original U19 cooperative agreement (RFA-NS-19-012) and advance national priorities described in the National Plan to Address Alzheimer"s Disease.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from Massachusetts General Hospital. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Classifications
- NAICS93.853
Documents (1)
- DownloadRFA-NS-27-011-Full-Announcement.htmltext/html;charset=UTF-8177 KB
Contacts
Similar contracts
- NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)Due Mar 9, 2029
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)Due Apr 5, 2029
- NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed)Due Jul 10, 2026
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)Due Nov 10, 2026
- Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)Due Oct 8, 2027
- HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)Due Jul 16, 2026